Avzivi® (BAT1706) is Bio-Thera Solution’second FDA approved product in the United States Avzivi® is the second biosesimilar researched,developed, and manufactured by a Chinese pharmaceutical company to receive FDAapproval in the United States Guangzhou, China – December 7, 2023 – Bio-TheraSolu...
DetailsGUANGZHOU, China--( BUSINESS WIRE )--Bio-Thera Solutions, Ltd., a clinical-stage pharmaceutical company, today announced that the China National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application to initiate a Phase I clinical study to compare the phar...
GUANGZHOU, China--( BUSINESS WIRE )--Bio-Thera Solutions, Ltd., a clinical-stage pharmaceutical company, today announced that the China National Medical Products Administration (NMPA) has approved QLETLI ® (格乐立 ® ) for all eligible indications of the reference product, Humira ® (adalimumab)...
Bio-Thera Solutions, a clinical-stage biopharmaceutical company developing a pipeline of innovative oncology therapies and a pipeline of biosesimilars, today announced the company will present two posters at the 2019 American Association for Cancer Research ("AACR") Annual Meeting taking place March 2...
